The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist

Biochemical and Biophysical Research Communications

Volumn 375, Issue 4, 2008, Pages 562-565

  Tang, Hua ^a   Lu, Jenny Ying Lin ^a   Zheng, Xiaomu ^a   Yang, Yuhua ^a   Reagan, Jeff D ^a  

^a AMGEN INC   (United States)

Author keywords

BG 12; Fumaderm; Fumarate ester; GPR109A; Keratinocyte; Monomethylfumarate; Multiple sclerosis; Niacin; Nicotinic acid; Psoriasis

Indexed keywords

AEQUORIN; CALCIUM; CYCLIC AMP; DRUG METABOLITE; FUMADERM; MONOMETHYLFURAMATE; NICOTINIC ACID; NICOTINIC AGENT; NICOTINIC RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG IDENTIFICATION; HUMAN; HUMAN CELL; KERATINOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTILIPEMIC AGENTS; CELL LINE; DERMATOLOGIC AGENTS; FUMARATES; HUMANS; MALEATES; NIACIN; PSORIASIS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NICOTINIC;

MUS;

EID: 51649111846     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.08.041     Document Type: Article

References (26)

1. Lorenzen A., Stannek C., Lang H., Andrianov V., Kalvinsh I., and Schwabe U. Characterization of a G protein-coupled receptor for nicotinic acid. Mol. Pharm. 59 (2001) 349-357
2. Tunaru S., Kero J., Schaub A., Wufka C., Blaukat A., Pfeffer K., and Offermanns S. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat. Med. 9 (2003) 352-355
3. Wise A., Foord S.M., Fraser N.J., Barnes A.A., Elshourbagy N., Eilert M., Ignar D.M., Murdock P.R., Steplewski K., Green A., Brown A.J., Dowell S.J., Szekeres P.G., Hassall D.G., Marshall F.H., Wilson S., and Pike N.B. Molecular identification of high and low affinity receptors for nicotinic acid. J. Biol. Chem. 278 (2003) 9869-9874
4. Soga T., Kamohara M., Takasaki J., Matsumoto S.-I., Saito T., Ohishi T., Hiyama H., Matsuo A., Matsushime H., and Furuichi K. Molecular identification of nicotinic acid receptor. Biochem. Biophys. Res. Commun. 303 (2003) 364-369
5. Offermanns S. The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. Trends Pharm. Sci. 27 (2006) 384-390
6. Altschul R., Hoffer A., and Stephen J.D. Influence of nicotinic acid on serum cholesterol in man. Arch. Biochem. Biophys. 54 (1955) 558-559
7. Knopp R.H. Drug treatment of lipid disorders. N. Engl. J. Med. 341 (1999) 498-511
8. Szapary P.O., and Rader D.J. Pharmacological management of high triglycerides and low high-density lipoprotein cholesterol. Curr. Opin. Pharmacol. 1 (2001) 113-120
9. Shepherd J., Packard C.J., Patsch J.R., Gotto Jr. A.M., and Taunton O.D. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J. Clin. Invest. 63 (1979) 858-867
10. Karpe F., and Frayn K.N. The nicotinic acid receptor-a new mechanism for an old drug. Lancet 363 (2004) 1892-1894
11. Benyo Z., Gille A., Bennett C.L., Clausen B.E., and Offermans S. Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells. Mol. Pharm. 70 (2006) 1844-1849
12. Mrowietz U., Christophers E., and Altmeyer P. Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. Br. J. Dermatol. 141 (1999) 424-429
13. Asadullah K., Volk H.-D., Friedrich M., and Sterry W. Experimental therapies for psoriasis. Arch. Immunol. Ther. Exp. 50 (2002) 411-420
14. Hoefnagel J.J., Thio H.B., Willemze R., and Bouwes Bavinck J.N. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Brit. J. Dermatol. 149 (2003) 363-369
15. Harries M.J., Chalmers R.J.G., and Griffiths C.E.M. Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases. Br. J. Dermatol. 153 (2005) 549-551
16. iα. Nature 363 (1993) 274-276
17. i-coupled receptors. Anal. Biochem. 270 (1999) 242-248
18. Richman J.G., Kanemitsu-Parks M., Gaidarov I., Cameron J.S., Griffin P., Zheng H., Guerra N.C., Cham L., Maciejewski-Lenoir D., Behan D.P., Boatman D., Chen R., Skinner P., Ornelas P., Waters M.G., Wright S.D., Semple G., and Connolly D.T. Nicotinic acid receptor agonists differentially activate downstream effectors. J. Biol. Chem. 282 (2007) 18028-18036
19. Schweckendiek W. Die psoriasias vulgaris, eine stoffwechselbedingte Hautkrankheit. Erfahrungsheikunde 33 (1984) 850-858
20. Nieboer C., de hoop D., Langendijk P.N.J., van Loenen A.C., and Gubbels J. Fumaric acid therapy in psoriasis: a double-blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester. Dermatologica 181 (1990) 33-37
21. Schaub A., Fütterer A., and Pfeffer K. PUMA-G, an IFN-γ-inducible gene in macrophages is a novel member of the seven transmembrane spanning receptor superfamily. Eur. J. Immunol. 31 (2001) 3714-3725
22. Schimrigk S., Brune N., Hellwig K., Lukas C., Bellenberg B., Rieks M., Hoffmann V., Pöhlau D., and Przuntek H. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open label, baseline-controlled pilot study. Eur. J. Neurol. 13 (2006) 604-610
23. Kreuter A., Knierim C., Stücker M., Pawlak F., Rotterdam S., Altmeyer P., and Gambichler T. Fumaric acid esters in necrobiosis lipoidica: results of a prospective noncontrolled study. Br. J. Dermatol. 153 (2005) 802-807
24. BG 12: BG 00012, BG 12/Oral Fumarate, FAG-201, second-generation fumarate derivative-Fumapharm/Biogen Idec., Drugs R.D. 6 (2005) 229-230.
25. S. Swift, J. Lorens, P. Achacoso, G.P. Nolan, Curr. Protoc. Immunol. Unit 10.28 (Suppl. 31) (1999).
26. Reagan J. Expression cloning of a diuretic hormone receptor. J. Biol. Chem. 269 (1994) 7-12